ARK Stock Commentary: ABSI & ESLT

[!warning] Conflict of Interest ARK Invest is an active fund manager. These are stocks in ARK's own portfolios -- they are explaining moves in positions they hold. Read as promotional context, not independent analysis.

Movers (Week of Mar 16-21, 2026)

• ABSI (+21%): Absci outlined clinical milestones for ABS-201 (AI-designed antibody for hair loss). Preliminary safety/PK data expected H1 2026, interim hair growth data at week 13 in H2 2026, 26-week data early 2027. Management cited $20B+ US TAM. Also deploying Origin 2.0 AI model for de-novo antibody design internally.
• ESLT (+15%): Elbit Systems beat Q4 expectations on growing international defense demand amid geopolitical tensions. Record backlog of $28.1B, ~72% from orders outside Israel. Israeli defense company specializing in UAVs, avionics, surveillance, cyber systems.

RDCO Relevance

Absci is a data point for AI-driven drug discovery commercialization. Origin 2.0 generative AI for de-novo antibody design worth monitoring as AI-biotech convergence signal. Elbit defense backlog reflects geopolitical risk premium in defense sector.